MM+M Podcast 8.2.22: Could biopharma M&A ramp up in the second half?

Subin Baral, global life sciences deals leader at EY, shares his research-based predictions for where biopharma dealmaking could be headed in the second half.

MM+M Staff

August 2, 2022

1:02 pm

There are strong underlying reasons to suggest a return to large-scale — potentially even transformative — M&A in the coming months. Subin Baral, global life sciences deals leader at EY, shares his research-based predictions for where biopharma dealmaking could be headed in the second half.

From Our Partners

Taking a patient-centric approach to privacy

Partner Content

Taking a patient-centric approach to privacy

This podcast will explore ways to deliver tailored content that activates, educates and empowers patients while prioritizing privacy and consent.

Living brands: How to build brands in the age of omnichannel

Partner Content

Living brands: How to build brands in the age of omnichannel

This podcast looks at how to leverage advancements in data, technology, AI and content development in order to become a Living Brand.

Partner Content

The new brand.com experience

How healthcare manufacturers can improve customer engagement, drive high-value activity and inform future strategy with conversational AI.

Shifting market trends are transforming how pharma marketers find, target and engage with patients and providers

Partner Content

Shifting market trends are transforming how pharma marketers find, target and engage with patients and providers

The Healthcare Marketers Trend Survey shows that, as far as channel usage goes, more growth occurred in newer tactics like non-linear video and streaming audio than in some of the more traditional ones.